Page 28 - ARUBA TODAY
P. 28

A28    SCIENCE
                    Thursday 28 June 2018

            Enemy turned ally: Poliovirus is used to fight brain tumors




            By MARILYNN MARCHIONE
            AP Chief Medical Writer
            One  of  the  world’s  most
            dreaded  viruses  has  been
            turned into a treatment to
            fight  deadly  brain  tumors.
            Survival  was  better  than
            expected  for  patients  in  a
            small study who were given
            genetically  modified  po-
            liovirus,  which  helped  their
            bodies  attack  the  cancer,
            doctors report.
            It  was  the  first  human  test
            of  this  and  it  didn’t  help
            most  patients  or  improve
            median  survival.  But  many
            who  did  respond  seemed
            to  have  long-lasting  ben-
            efit: About 21 percent were
            alive  at  three  years  versus
            4 percent in a comparison
            group of previous brain tu-
            mor patients.
            Similar survival trends have
            been  seen  with  some  oth-
            er  therapies  that  enlist  the
            immune  system  against
            different  types  of  cancer.
            None are sold yet for brain
            tumors.  “This  is  really  a  first   This Aug. 8, 2013 photo provided by Duke University shows Dr. Matthias Gromeier at his laboratory at Duke in Durham, N.C.
            step,”  and  doctors  were                                                                                                      Associated Press
            excited to see any survival  Doctors  at  Duke  wanted  free,” he said.                more than three years ago.   Doctors stressed that these
            benefit  in  a  study  testing  to  take  advantage  of  the  STUDY RESULTS            Stephanie  Hopper,  27,  of   were  due  to  the  immune
            safety, said one researcher,  strong  immune  system  re-  The study tested the modi-  Greenville,  South  Carolina,   response  in  the  brain  and
            Duke University’s Dr. Annick  sponse it spurs to try to fight  fied  poliovirus  on  61  pa-  was the first patient treated   that no one got polio as a
            Desjardins.  Preliminary  re-  cancer.  With  the  help  of  tients  whose  tumors  had  in  the  study  in  May  2012   result of treatment.
            sults  were  to  be  discussed  the  National  Cancer  Insti-  recurred  after  initial  treat-  and  it  allowed  her  to  fin-  One  patient  had  serious
            Tuesday  at  a  conference  tute, they genetically mod-   ments. Median survival was  ish college and become a      brain  bleeding  right  after
            in  Norway  and  published  ified  poliovirus  so  it  would  about  a  year,  roughly  the  nurse.  Scans  as  recent  as   the  procedure.  Two  pa-
            online by the New England  not harm nerves but still in-  same  as  for  a  small  group  early  June  show  no  signs   tients  died  relatively  soon
            Journal of Medicine.         fect tumor cells.            of  similar  patients  given  that  the  tumor  is  growing,   after treatment — one from
            MAKING  AN  ENEMY  AN  The  treatment  is  dripped  other  brain  tumor  treat-        she  said.  “I  believe  whole-  worsening  of  the  tumor
            ALLY                         directly  into  the  brain  ments  at  Duke.  After  two  heartedly  that  it  was  the   and  the  other  from  com-
            Brain  tumors  called  glio-  through a thin tube. Inside  years,  the  poliovirus  group  cure for me,” she said. Her   plications  of  a  drug  given
            blastomas often recur after  the  tumor,  the  immune  started faring better.          only  lasting  symptom  has   to  manage  a  side  effect.
            initial treatment. Sen. John  system  recognizes  the  vi-  Follow-up is continuing, but  been seizures, which medi-  The  planned  doses  had
            McCain is being treated for  rus  as  foreign  and  mounts  survival  is  estimated  at  21  cines  help  control.  “Most   to  be  reduced  because
            one  now.  Immunotherapy  an  attack.  When  doctors  percent at two years versus  people wouldn’t guess that       there  were  too  many  sei-
            drugs  like  Keytruda  help  explained  the  idea  to  Mi-  14 percent for the compar-  I had brain cancer.”        zures  and  other  problems
            fight  some  cancers  that  chael  Niewinski,  it  seemed  ison group. At three years,  SIDE EFFECTS                at the higher doses initially
            spread  to  the  brain  but  a feat “like putting a man  survival was still 21 percent  The  treatment  causes  a   chosen.
            have  not  worked  well  for  on the moon,” he said. The  for the virus group versus 4  lot  of  brain  inflammation,   One  independent  expert,
            ones that start there.       33-year-old  from  Boca  Ra-  percent for the others.     and  two  thirds  of  patients   Dr.  Howard  Fine,  brain  tu-
            Polio  ravaged  generations  ton,  Florida,  was  treated  Eight of the 35 patients who  had  side  effects.  The  most   mor  chief  at  New  York-
            until  a  vaccine  came  out  last August, and said a re-  were  treated  more  than  common ones were head-        Presbyterian and Weill Cor-
            in  the  1950s.  The  virus  in-  cent scan seemed to show  two  years  ago  were  alive  aches,  muscle  weakness,   nell  Medicine,  said  it  was
            vades  the  nervous  system  some tumor shrinkage.        as  of  March,  as  were  five  seizure,  trouble  swallowing   disappointing  to  see  no
            and  can  cause  paralysis.  “I’m  pain-free,  symptom-   out  of  22  patients  treated  and  altered  thinking  skills.   improvement  on  median
                                                                                                                                survival,  but  encouraging
                                                                                                                                to  see  “extraordinary  re-
                                                                                                                                sponders, a small group of
                                                                                                                                patients  who  have  done
                                                                                                                                markedly  better  than  one
                                                                                                                                would expect.”
                                                                                                                                The  numbers  in  the  study
                                                                                                                                are small, but it’s unusual to
                                                                                                                                see many alive after sever-
                                                                                                                                al years, and suggests the
                                                                                                                                approach merits more and
                                                                                                                                bigger studies, he said.q
   23   24   25   26   27   28   29   30   31   32